| Stereochemistry | ABSOLUTE |
| Molecular Formula | C33H34N4O3 |
| Molecular Weight | 534.6481 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(N[C@@H]1C(=O)N(CC23CC4CC(CC(C4)C2)C3)C5=CC=CC=C5N(C6=CC=CC=C6)C1=O)NC7=CC=CC=C7
InChI
InChIKey=RZERRLOTRSJIAW-NEPGVILWSA-N
InChI=1S/C33H34N4O3/c38-30-29(35-32(40)34-25-9-3-1-4-10-25)31(39)37(26-11-5-2-6-12-26)28-14-8-7-13-27(28)36(30)21-33-18-22-15-23(19-33)17-24(16-22)20-33/h1-14,22-24,29H,15-21H2,(H2,34,35,40)/t22?,23?,24?,29-,33?/m1/s1
| Molecular Formula | C33H34N4O3 |
| Molecular Weight | 534.6481 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
|
|
ACTIVE MOIETY |
Phase II clinical trials for anxiety and sleep disorders.
|
Showing 1 to 1 of 1 entries